AZ sells Insmed rights to respiratory drug
AstraZeneca has sold rights to experimental respiratory drug AZD7986 to US biotech Insmed in a deal valued at around $150 million.
Read More
Tag: Insmed
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
